GLP-1 Constipation: Why It Happens and What Each Label Lists

GLP-1 constipation has two causes that reinforce each other, and both can be traced to a named source: the FDA labels for the first, and the NIH's NIDDK for the second. The first is pharmacological. Semaglutide, tirzepatide and liraglutide all act on the GLP-1 receptor, and one of the receptor's jobs is to slow the movement of food out of the stomach. The FDA prescribing information for Ozempic (Novo Nordisk), section 12.2, states that semaglutide causes a delay of early postprandial gastric emptying. The Mounjaro label from Eli Lilly, also section 12.2, states that tirzepatide delays gastric emptying and that the delay is largest after the first dose and diminishes over time. The Saxenda label carries the same statement for liraglutide. The labels stop at gastric emptying and do not describe transit further down the gut, so the link between slower emptying and harder stool is not something the labels themselves state.

The second cause is behavioral, and it follows directly from the drug working as intended. Appetite falls, portions shrink, and many people also drink less because they simply feel full. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the NIH, lists not eating enough fiber, not drinking enough liquids and not getting enough physical activity among the common causes of constipation in the general population. A smaller appetite tends to reduce all three at once, because the foods that supply fiber are bulky and the fluid that usually arrives with meals arrives less often.

That is why constipation on a GLP-1 does not behave like the nausea. The Ozempic label notes that most nausea, vomiting and diarrhea reports occurred during dose escalation; the Mounjaro and Zepbound labels add that they decreased over time. Constipation is driven partly by how you are eating, so it can persist for as long as intake stays low, which is exactly why it is worth tracking rather than assuming it will fade on its own. If nausea is also part of your picture, the companion page on GLP-1 nausea tips covers that separately.

The figures below come from the adverse-reaction tables in the current FDA prescribing information for each product, read on DailyMed, the National Library of Medicine's label repository. Each table reports the percentage of trial participants who reported constipation at least once, alongside the placebo group. Trial populations differ (type 2 diabetes for Ozempic, Mounjaro and Rybelsus; obesity or overweight for Wegovy, Zepbound and Saxenda), and every label warns that rates from one drug's trials cannot be directly compared with another's. Read them as a range, not a ranking.

Ozempic (semaglutide injection, Novo Nordisk), label revised May 2026, Table 1, pooled placebo-controlled trials in adults with type 2 diabetes: constipation in 5% and 3.1% of participants across the two doses studied, versus 1.5% on placebo.

Wegovy (semaglutide injection, Novo Nordisk), label revised June 2026, Table 3, three pooled placebo-controlled trials of 2,116 adults with obesity or overweight treated for up to 68 weeks: constipation in 24%, versus 11% on placebo. The same label notes that gastrointestinal reactions were most frequently reported during dosage escalation.

Mounjaro (tirzepatide injection, Eli Lilly), label revised August 2026, Table 1, pooled SURPASS-1 and SURPASS-5 trials in adults with type 2 diabetes: constipation in 6%, 6% and 7% across the three doses studied, versus 1% on placebo. In the separate cardiovascular outcomes trial, the label reports constipation in 13%.

Zepbound (tirzepatide injection, Eli Lilly), label revised August 2026, Table 1, pooled Study 1 and Study 2 of 2,519 adults with obesity or overweight treated for up to 72 weeks: constipation in 17%, 14% and 11% across the three doses studied, versus 5% on placebo. The table's footnote says the term includes constipation and hard feces.

Rybelsus (semaglutide tablets, Novo Nordisk), label revised January 2026, Table 2, two placebo-controlled trials in adults with type 2 diabetes: constipation in 6% and 5% across the two doses studied, versus 2% on placebo.

Saxenda (liraglutide injection, Novo Nordisk), label revised June 2026, Table 2, five placebo-controlled trials of 3,384 adults treated for up to 56 weeks: constipation in 19.4%, versus 8.5% on placebo.

Two patterns stand out. The weight-management products (Wegovy, Zepbound, Saxenda) report higher constipation rates in their pooled tables than the diabetes products' pooled tables do; the labels do not say why, and they warn against comparing across trials. And in every table the medication arm exceeds placebo.

The three measures that come up most often in conversations about GLP-1 constipation map directly onto the three lifestyle causes the NIDDK names: fluid, fiber and physical activity. That alignment is the reason they are worth raising, and it is also the reason this page will not tell you how much of any of them to have. Amounts depend on your size, your other medications, your kidney and heart health and what your prescriber already knows about you.

Fluid is the one most people underestimate, because a full-feeling stomach quietly cuts drinking as well as eating. The scenario page on how much water to drink on a GLP-1 walks through the reasoning without pretending there is one number for everyone. Fiber is the second, and the NIDDK's eating and nutrition guidance for constipation is specific about the pace: add fiber to your diet a little at a time so your body gets used to the change, and drink water and other liquids to help the fiber work better. How quickly to build it up in your case is something a pharmacist or dietitian can help you pace. The foods to avoid on a GLP-1 guide covers the meals that tend to sit heavily, which overlaps with this problem from the other direction. Movement is the third: the NIDDK lists too little physical activity as a cause, and a daily walk is the version most people can actually keep.

Then there are the products. Pharmacy shelves hold fiber supplements, stool softeners, osmotic laxatives and stimulant laxatives, and they are not interchangeable. Which one is appropriate, whether any is appropriate at all, how long it is reasonable to use it, and whether it interacts with anything else you take are questions your pharmacist answers in a two-minute conversation and a website cannot answer responsibly. Bring your medication list, say which GLP-1 you are on and how long the constipation has lasted, and ask. If something is not working after the period the pharmacist suggested, that is information for your prescriber, not a reason to try a stronger product on your own.

Most GLP-1 constipation is uncomfortable rather than dangerous, but the labels are explicit that a serious end of the spectrum exists. Every one of the six labels now carries a Warnings and Precautions section on severe gastrointestinal adverse reactions, and their postmarketing sections (section 6.2) report ileus, intestinal obstruction and severe constipation including fecal impaction with semaglutide, tirzepatide and liraglutide. The Wegovy label additionally states that severe gastrointestinal reactions were reported in 4.1% of injection-treated adults versus 0.9% on placebo, and that Wegovy is not recommended in patients with severe gastroparesis.

The signs that should prompt a call rather than a wait are consistent across the labels' Medication Guides and the NIDDK's guidance. The Wegovy Medication Guide from Novo Nordisk gives specific instructions for severe pain in the stomach area that will not go away, with or without nausea or vomiting, and notes the pain can be felt through to the back, because that pattern can signal pancreatitis rather than constipation. The NIDDK lists bleeding from the rectum, blood in the stool, constant pain in the abdomen, inability to pass gas, vomiting, fever, lower back pain and losing weight without trying as symptoms that need medical attention.

On the question of how many days without a bowel movement is too many: the labels do not set a number, and neither should this page. The NIDDK defines constipation as fewer than three bowel movements a week or stools that are hard, dry, lumpy, difficult or painful to pass, and adds that only you know what is normal for you. That is the honest baseline. If your normal has changed, or if any of the signs above appear at any point, the Medication Guide's own instruction applies: talk to your healthcare provider about any side effect that bothers you or does not go away. Whether to hold or continue a dose is your prescriber's call, and the Medication Guide for your product says what to do in an emergency.

Constipation is a slow symptom, which makes it a poor fit for memory. By the time an appointment arrives, most people can say it has been a problem but cannot say when it started, whether it tracks their dose days, or whether the week they drank more actually helped. A short daily record answers those questions, and it changes the conversation from a complaint into a data set your prescriber can act on.

Five fields do most of the work. First, bowel movements: the date, and a one-word note on ease or difficulty. Second, fluid, even roughly, because the days you barely drank tend to line up with the days that went badly. Third, fiber-rich meals, since a photo of the plate is faster than a description and shows whether the vegetables and whole grains actually made it in. Fourth, dose days, so you can see whether things worsen in the days after an injection or tablet. Fifth, any discomfort, bloating or pain, with its date, so severity has a timeline rather than an adjective.

GLP-1 Tracker is built to hold exactly this. Side-effect notes, meal photos with a protein and fiber estimate, and the dose log sit on one timeline on your iPhone, so at the appointment you scroll rather than reconstruct. The app records what you enter and stores it on your device; it does not interpret the pattern, diagnose anything, or offer any guidance on your medication. That reading is your prescriber's job, and a clear record simply makes it a shorter one.

This is a general education page from an independent app developer, not medical advice, and it deliberately stays inside one question: why GLP-1 constipation happens, what the labels list, and what to watch and log. It does not tell you how much fluid or fiber to have, which product to buy, or anything about how or when to take your medication, because those answers depend on facts about you that a web page cannot see. The rates quoted are the labels' own trial figures as of their 2026 revisions; labels change, and the current version on DailyMed always supersedes anything written here.

Ozempic, Wegovy, Rybelsus and Saxenda are trademarks of Novo Nordisk; Mounjaro and Zepbound are trademarks of Eli Lilly. GLP-1 Tracker is not affiliated with, sponsored by or endorsed by either company, and the brand names appear here only because they are the medications people track. Your prescriber and your pharmacist are the two people who can turn the information above into a plan for you.